Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) Return on Sales (2020 - 2025)

Historic Return on Sales for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to 42.49%.

  • Insight Molecular Diagnostics' Return on Sales rose 750300.0% to 42.49% in Q3 2025 from the same period last year, while for Sep 2025 it was 13.93%, marking a year-over-year increase of 245400.0%. This contributed to the annual value of 32.45% for FY2024, which is 305000.0% down from last year.
  • Per Insight Molecular Diagnostics' latest filing, its Return on Sales stood at 42.49% for Q3 2025, which was up 750300.0% from 19.0% recorded in Q2 2025.
  • Insight Molecular Diagnostics' Return on Sales' 5-year high stood at 1.95% during Q4 2023, with a 5-year trough of 120.3% in Q4 2022.
  • For the 5-year period, Insight Molecular Diagnostics' Return on Sales averaged around 35.81%, with its median value being 22.63% (2024).
  • Its Return on Sales has fluctuated over the past 5 years, first soared by 6166400bps in 2021, then crashed by -1103500bps in 2022.
  • Over the past 5 years, Insight Molecular Diagnostics' Return on Sales (Quarter) stood at 9.94% in 2021, then tumbled by -1110bps to 120.3% in 2022, then soared by 98bps to 1.95% in 2023, then tumbled by -1062bps to 22.63% in 2024, then plummeted by -88bps to 42.49% in 2025.
  • Its Return on Sales was 42.49% in Q3 2025, compared to 19.0% in Q2 2025 and 3.18% in Q1 2025.